Download presentation
Presentation is loading. Please wait.
Published byKai Dale Modified over 5 years ago
1
TCR stimulation by agonistic mAb in vivo administration inhibits mouse T-ALL development.
TCR stimulation by agonistic mAb in vivo administration inhibits mouse T-ALL development. A and B, percentage of TEL-JAK2/TCR-HY leukemic cells in peripheral blood (PB; A) and Kaplan–Meier survival curves (B) of female mice treated daily as indicated (arrows) with hamster anti-CD3 mAb or control IgG. C, percentage of TEL-JAK2 leukemic cells (expressing endogenous TCR) in peripheral blood leukocytes of mice that were treated daily with anti-CD3 or control hamster IgG. D, Kaplan–Meier survival curves of mice injected with either TEL-JAK2 leukemic cells (expressing endogenous TCR), or TEL-JAK2/CD3ε−/− leukemic cells and treated daily with anti-CD3 or control hamster IgG. E, percentage of IKL/L leukemic cells in peripheral blood leukocytes defined as FSChi, Thy1.2+ CD25+ in control IgG or anti-CD3–treated NOD/SCID/γc−/− (NSG) mice at the indicated time point. F, Kaplan–Meier survival curves of NSG mice injected with IKL/L leukemic cells treated with hamster anti-CD3 mAb or control IgG as indicated. Amélie Trinquand et al. Cancer Discov 2016;6: ©2016 by American Association for Cancer Research
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.